Previous 10 | Next 10 |
2023-05-02 16:21:07 ET Cytosorbents press release ( NASDAQ: CTSO ): Q1 GAAP EPS of -$0.17 misses by $0.02 . Revenue of $9.44M (+8.6% Y/Y) beats by $0.71M . For further details see: Cytosorbents GAAP EPS of -$0.17 misses by $0.02, revenue of $9.44M beats b...
PRINCETON, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported una...
MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2023 operating and financial re...
PRINCETON, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that its p...
PRINCETON, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today ...
PRINCETON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, highlights the recently published study entitled, “ Cyto...
PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced its scientific program for the 42 nd Internatio...
PRINCETON, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today ...
2023-03-09 23:32:06 ET Cytosorbents Corporation (CTSO) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jodi Hoover – Manager-Clinical Administration Phillip Chan – Chief Executive Officer Irina Kulinets – Senior...
2023-03-09 16:20:59 ET Cytosorbents press release ( NASDAQ: CTSO ): FY GAAP EPS of -$0.75 beats by $0.14 . Revenue of $29.36M (-26.8% Y/Y) misses by $4.69M . Grant Income, was $9.4 million versus $10.8 million in Q4 2021, a decrease of 13% Product Sales wer...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...